Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of TGKP in Healthy Volunteers
NCT06127381Phase 1Unknown
- Start
- Nov 2023
- Primary completion
- Apr 2024
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of piceatannol tetraglycolate in acute respiratory distress syndrome (ARDS) (3 arms). Primary endpoints: Occurrence of Adverse Events at 28 days and Occurrence of Serious Adverse Events at 28 days. Status: unknown.
02
Drugs
piceatannol tetraglycolate
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT06127381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06127381.